Logo

ALUR

Allurion Technologies Inc.

ALUR

Allurion Technologies Inc. • NYSE
$1.54 ▼ -4.35% (-0.07)
Market Cap $11.96 M
52w High $16.81
52w Low $1.02
Dividend Yield 0%
P/E -0.1
Volume 88.22K
Outstanding Shares 7.77M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $2.658M ▼ $10.934M ▲ $-11.884M ▼ -447.103% ▼ $-1.53 ▼ $-11.607M ▼
Q2-2025 $3.379M ▼ $9.449M ▼ $-9.335M ▼ -276.265% ▼ $-1.28 ▼ $-8.945M ▼
Q1-2025 $5.58M ▼ $11.443M ▼ $-1.501M ▲ -26.9% ▲ $-0.31 ▲ $7.677M ▲
Q4-2024 $5.591M ▲ $19.648M ▲ $-20.568M ▼ -367.877% ▼ $-7.94 ▼ $-20.496M ▼
Q3-2024 $5.367M $15.452M $-9.004M -167.766% $-3.51 $-8.527M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $6.136M ▼ $18.141M ▼ $101.069M ▲ $-82.928M ▼
Q2-2025 $12.722M ▼ $28.169M ▼ $92.145M ▼ $-63.976M ▲
Q1-2025 $20.408M ▲ $38.414M ▲ $108.204M ▼ $-69.79M ▲
Q4-2024 $15.379M ▼ $32.813M ▼ $110.791M ▼ $-77.978M ▼
Q3-2024 $28.654M $50.699M $114.51M $-63.811M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-11.884M ▲ $-6.544M ▲ $0 $-55K ▲ $-6.586M ▲ $-6.544M ▲
Q2-2025 $-18.215M ▼ $-7.613M ▲ $0 $-71K ▼ $-7.684M ▼ $-7.613M ▲
Q1-2025 $7.379M ▲ $-9.469M ▲ $0 $14.499M ▲ $5.03M ▲ $-9.469M ▲
Q4-2024 $-20.569M ▼ $-13.274M ▼ $0 ▲ $-53K ▼ $-13.327M ▼ $-13.274M ▼
Q3-2024 $-9.004M $-11.463M $-72K $20.934M $9.399M $-11.535M

Five-Year Company Overview

Income Statement

Income Statement Allurion looks like an early‑stage medical device company that is still very much in the “build” phase. Revenue is tiny and has not yet scaled to a level that can support the cost structure. Gross profit is positive, which suggests the core product can be sold at a markup, but operating expenses are heavy, leading to steady operating and net losses each year. Losses peaked recently and then narrowed somewhat in the latest year, which hints at some cost control or improving efficiency, but the business is clearly not close to profitability. Overall, this is a company investing heavily ahead of revenue, with financial results that reflect an emerging, not yet mature, commercial model.

Balance Sheet

Balance Sheet The balance sheet is thin and highly stretched. Total assets are modest, and cash makes up a large share of them, which is typical for a young, R&D‑driven company. Debt levels are similar to or above the asset base, and shareholder equity has been negative for several years, meaning accumulated losses have more than wiped out contributed capital. This structure signals financial fragility and dependence on lenders and new capital infusions. The recent reverse split is a capital‑markets move rather than an operational change, but it underlines the company’s need to remain market‑accessible to fund its strategy.

Cash Flow

Cash Flow Cash flow tells the same story as the income statement: the company is burning cash. Operating cash flow has been consistently negative as the company spends on R&D, clinical programs, commercialization, and its digital platform. Free cash flow is also clearly negative, though the business does not appear to be very capital‑intensive in terms of physical assets. With little or no offset from asset sales or other sources, the company likely relies on external financing to cover its cash burn. The key uncertainty is how long its cash resources and funding access can support this pace of spending if revenue does not ramp meaningfully.

Competitive Edge

Competitive Edge Strategically, Allurion sits in an attractive but fiercely competitive niche: obesity and weight management. Its main differentiator is a swallowable, procedure‑less gastric balloon paired with a data‑rich digital care platform and AI coaching. This combination gives it a unique, less invasive option compared with traditional endoscopic balloons and a more holistic program compared with many standalone treatments. A growing base of clinical data and international presence adds credibility. However, the rise of powerful weight‑loss drugs and the presence of much larger medical and pharmaceutical players make this a crowded field. Allurion is trying to position itself not as a direct rival to drugs but as a complementary solution, which could be an advantage if it can prove better long‑term outcomes and muscle preservation. Market education, reimbursement, and regulatory progress—especially in the U.S.—are critical factors for its competitive standing.

Innovation and R&D

Innovation and R&D Innovation is the core of Allurion’s story. The company has pioneered a swallowable, procedure‑less balloon and built an AI‑enabled virtual care suite that integrates devices, coaching, and predictive analytics. It is actively expanding its patent portfolio and pursuing next‑generation products, including advanced balloon designs and the possibility of a drug‑eluting balloon that combines mechanical restriction with GLP‑1‑type effects in a single device. It is also investing in clinical trials for combination therapy with GLP‑1 drugs and enhancing its AI coaching and remote monitoring capabilities. This R&D intensity helps build a technological and data moat, but it also drives the high expense base and cash burn seen in the financials. The payoff depends on regulatory approvals, clinical validation, and successful commercialization of these innovations.

Summary

Overall, Allurion is an innovation‑driven, early‑stage healthcare company with a novel weight‑loss platform but a financially fragile profile. The product and digital ecosystem are differentiated and backed by growing clinical and AI capabilities, which could support a durable niche if adoption scales and combination strategies with weight‑loss drugs succeed. At the same time, revenue remains very small, losses are substantial, equity is negative, and cash flows are clearly negative, implying an ongoing need for external funding. Future outcomes hinge on a few major swing factors: regulatory approvals (particularly in the U.S.), proof that its program adds value alongside GLP‑1 drugs, the ability to convert clinical data into broad commercial uptake, and disciplined management of its balance sheet and cash burn in a very competitive obesity market.

NEWS

November 25, 2025 · 9:25 AM UTC

Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence

Read more

November 20, 2025 · 9:00 AM UTC

New Peer-Reviewed Publication Demonstrates Superior Weight Loss and Improved Body Composition with the Allurion Smart Capsule Combined with Lifestyle Intervention Compared to Lifestyle Intervention Alone

Read more

November 18, 2025 · 9:00 AM UTC

Allurion Announces Strategic Distribution Partnership with ProSurg Medical in Brazil to Pioneer New Approach Focused on Metabolically Healthy Weight Loss

Read more

November 12, 2025 · 8:00 AM UTC

Allurion Reports Third Quarter 2025 Financial Results and Provides Business Update

Read more

November 11, 2025 · 8:45 AM UTC

Allurion Passes Critical FDA Milestones, Enters Into Transaction to Exchange All Outstanding Debt That Would Result in the Company Being Debt-Free, and Announces a $5 Million Private Placement Financing

Read more